Preliminary program
(per 2026-03-11)
September 17, 2026 – P53 Focus Day
08.00 – 08:45 | Registration
08:45 – 09:00 | Welcome and Opening [Bjørn Tore Gjertsen, chair, NAMLG]
Session 1
[Chairs: Bjørn Tore Gjertsen, Marianne Severinsen]
09:00 – 09:40 | David Lane, NAMLG Keynote Lecture
09:40 – 10.00 | Christer Nilsson, Swedish AML Group: TP53 in AML
10:00 – 10:45 Coffee break
Session 2
[Chairs: Anne Louise Tølbøll Sørensen, Pia Ettala]
10:45 – 11:15 | Marina Konopleva, SKGJ CMYC Keynote Lecture
11:15 – 11:30 | Amos Tuval
11:30 – 12.00 | Jean-Christophe Bourdon, SKGJ CMYC Keynote Lecture
12:00 – 13:15: Lunch break
Session 3
[Chairs: Sören Lehmann, Albin Österroos]
13:15 – 13:45 | Klas Wiman, KG Jebsen Centre Keynote Lecture
13:45 – 14:00 | Anders Eivind Leren Myhre, TP53-Mutated Myeloid Neoplasms: Allo-HSCT at Any Cost?
14:00 – 14:15 | Tor Henrik Tvedt
14:15 – 14:45 | Shah Mithun
14:45 – 15:30 | Coffee break
Session 4
[Chairs: Håkon Reikvam, Andrea Lenartova]
15:30 – 16:10 | Kim Theilgaard-Mønch, NAMLG Keynote Lecture
16:10 – 16:30 | To be decided
16.30 – 16.50 | Hussain Abbas
17:00 – 18:00 | Industry sponsored Session #1, Otsuka
[Chair: TBD]
Title TBA; Focus on updated treatment landscape for elderly and fragile AML patients
18:10 – 19:10 | Led by Jörg Cammenga – Poster-walk with microphone; 2 min per poster; Academic and Industry presenting their posters, Snacks + drinks
19:30 – 22:30 | Conference Dinner @ Håkonshallen
September 18, 2026 – FLT3 Focus Day
08.00-09.00 | Industry Sponsored Session #2, Daiichi Sankyo
[Chair: TBD]
08:00 – 08:30 | Pau Montesinos, Clinical development of FLT3/TKI inhibitors in wild type AML: fails and successes
08:30 – 09:00 | Mark J Levis, Management of FLT3-ITD AML
Session 6
[Chairs: Jörg Cammenga,. Anne Sophie von Krogh]
09:00 – 09.30 | Lars Rönnstrand
09.30 – 10.00 | Gunnar Juliusson
10:00 – 10:45 | Coffee break
Session 7
[Chairs: Anne Stridsholt Roug, Daniel Tuyet Kristensen]
10:45 | Announcement of Poster Prizes
10:45 – 11:15 | Jing Tang,
11:15 – 11:45 | Ton Falques,
11.45-12.05 | Yngvar Fløysand,
12.05-12.25 | Marc Raajimakers,
12:25 – 13:30 | Lunch break
Session 8
[Chair: Bjørn Tore Gjertsen, Sören Lehmann]
13:30 – 13.50 | Pau Montesinos, Why and how should FLT3 inhibitors work in FLT3wt AML?
13:50 – 14.30 | Mark J Levis, Using MRD to manage FLT3-mutated AML
14:30 – 14.50 | Francesca Sacco, How the FLT3-ITD insertion site shapes therapy resistance: a systems biology approach
14:50 – 15:00 | Bjørn Tore Gjertsen, Closing remarks
